“Is it working?” sounds like one question. A cohort study at a Bucharest diabetes center treated it as four, scoring each patient separately on blood sugar, fat mass, inflammation and grip strength after twelve months on a stable regimen [1]. Most people passed one and failed the others. Who responds at all, and how early you can tell, is covered in slow responders at week eight.
The largest group, 53.0%, improved on blood sugar without meeting the fat mass threshold. Only 29.5% did both. A small 5.4% moved fat mass without moving blood sugar, and 12.0% did neither. Taken across all four measures, 47.0% counted as high responders and 15.1% responded on every dimension.
One limitation matters more than the rest for anyone reading this as a drug comparison. This is not a GLP-1 study. It is a cohort on metformin-based regimens in which GLP-1 drugs were one of six add-on options across 166 completers, so the subgroup taking one is small and its size is not stated. The observation that GLP-1 drugs showed the most consistent combined blood-sugar-and-fat-mass response, while insulin was predominantly blood-sugar-only, is a direction rather than a measured comparison, and should not be read as a head-to-head result.
The idea underneath is still worth carrying to a purchase. A seller’s before-and-after reports one number, usually weight, and this study is a reminder that weight moving and metabolic health improving are separate events that often do not coincide. That is also why a grip strength dimension belongs in the scoring at all, and why what patients themselves report as improvement rarely reduces to a number on a scale, as what patients said when asked describes. The cost of losing the wrong tissue is in the cost nobody prices, keeping muscle.
For a reader deciding whether their own treatment is working, the practical translation is to ask what is being measured before accepting the answer. Weight alone is the cheapest thing to measure and the least informative on its own, which is part of why published figures vary as much as they do in the super-responder brand comparison.